戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (right1)

通し番号をクリックするとPubMedの該当ページを表示します
1 le range, 14.8-33.4) months, 52 deaths and 24 heart failure events occurred.
2 4,311 person-years of follow-up in 2007-2017, 7,779 primary events occurred.
3          No drug-related serious treatment-emergent adverse events occurred.
4 esting ECGs obtained from 253,397 patients, in which 99,371 events occurred.
5              During 19 years (median) of follow-up, 461 CKD events occurred.
6                       No grade 5 treatment-emergent adverse events occurred; 5 patients died, including 3 after transplan
7                                         Results: No adverse events occurred after injection of (18)F-SKI.
8                                      No significant adverse events occurred after placebo or MSG administration, and vita
9         Over 3 years follow-up (SCI-Diabetes: 6 years), CVD events occurred among 27 900 (27%) CPRD-T2D, 101 362 (31%) SC
10                     No intervention-related serious adverse events occurred, and few adverse effects occurred after in-co
11              However, it is unclear whether super-spreading events occurred during the early outbreak phase, as has been
12                                  No related serious adverse events occurred during the second year.
13                                       Three serious adverse events occurred during the study (pulmonary embolism and myoc
14                                             Serious adverse events occurred equally between groups.
15                                             Serious adverse events occurred in 10% of participants on mavacamten and in 2
16                           Serious treatment-related adverse events occurred in 11 (10%) patients, of which neutropenia an
17                                    Nonfatal serious adverse events occurred in 12/72 (16.7%) in the oral group and 13/77
18           In IPV-vaccinated participants, solicited adverse events occurred in 16 (94%) of 17 who received novel OPV2-c1
19                                   Grade 3 or higher adverse events occurred in 190 patients (25.7%) who received T-DM1 an
20  3.7 years of follow-up, 3,417 total serious cardiovascular events occurred in 2,003 individuals among the 10,061 unique
21                                             Serious adverse events occurred in 22.7% and 21.7%, respectively.
22                           Treatment-related serious adverse events occurred in 25 (24%) patients and treatment-related de
23                         Grade 3 or 4 nonhematologic adverse events occurred in 25 patients (28%) on lenalidomide.
24                                             Serious adverse events occurred in 250 (45%) of 559 patients in the ferric ca
25                                               Major adverse events occurred in 3 patients (5.8%): one had transient diaph
26                                             Serious adverse events occurred in 33 (10%) of 332 patients in the experiment
27 nt times were 5(IQR: 4-6) and 6(IQR: 5-7) min, mild adverse events occurred in 4(9.4%) and 4(14.2%) of cases, and clinica
28 racheal intubation-associated events or oxygen desaturation events occurred in 40.2% of patients with reported difficult
29                                                  GI adverse events occurred in 42 patients (41%) after a median of 62 day
30                                   Treatment-related adverse events occurred in 5.3% vs 7.0% (UC) and 8.7% vs 19.0% (CD) o
31                      Grade 3 to 5 treatment-related adverse events occurred in 5.7% (n = 6) of patients.
32                        Treatment-emergent grade 3-4 adverse events occurred in 59% receiving pembrolizumab and 38% of pat
33                                   Treatment-related adverse events occurred in 66.7% of patients (n = 70), the most commo
34                                              Major bleeding events occurred in 71 (1.7%) of 4139 patients in the control
35                                           Grade 3-4 adverse events occurred in 71 (91%) of 78 patients in the 20 mg three
36                                                     Adverse events occurred in 89.3% of patients, the most common of whic
37                          Serious treatment-emergent adverse events occurred in 93 (48%) patients in the venetoclax group
38                         Grade 1-2 treatment-related adverse events occurred in 93% of patients, most commonly (>= 25%) fa
39                                           No severe adverse events occurred in any of the procedures.
40                           Treatment-related serious adverse events occurred in seven (12%) patients in the atezolizumab p
41                           Treatment-related serious adverse events occurred in six (14%) of 42 patients and were pneumoni
42                                Two primary safety end-point events occurred in the ablation group (Kaplan-Meier estimate
43                                                More adverse events occurred in the dexamethasone group than in the placeb
44             Over a median of 3.2 years, 318 primary outcome events occurred in the invasive-strategy group and 352 occurr
45 e death, one nonfatal stroke, and two venous thromboembolic events occurred in the upadacitinib group, and more patients
46                        Four non-DBS-related serious adverse events occurred, including one suicide attempt.
47                                              Intraoperative events occurred more frequently in high-severity versus low-s
48                                       Although these kidney events occurred more frequently in the intensive treatment gr
49        No major device-related or procedural-related safety events occurred up to 3 months.
50  traversal, inferring on which edges insertion and deletion events occurred using those internal node decorations.